Introduction
Acute decompensated heart failure (ADHF) represents new or worsening symptoms of heart failure that necessitate hospitalization.
1,2 As a leading cause of hospitalization in patients older than 65 years, ADHF is one of the most costly cardiovascular disorders. 3, 4 Acute decompensated heart failure is associated with severe cardiac diseases, and comorbidities including diabetes and renal disease. 5 Activation of soluble guanylate cyclase (sGC) is attracting increasing interest as a therapeutic strategy for cardiovascular disease. Conventional therapy for ADHF includes diuretics, positive inotropes, and organic nitrates. However, organic nitrates are associated with tachyphylaxis and cytotoxicity from peroxynitrite production. 6, 7 There is a need for a therapeutic agent that will safely improve the haemodynamics in patients with ADHF, without adversely affecting the heart and kidneys. Cinaciguat (BAY 58-2667), a novel, potent sGC activator in clinical † Some parts of this study were presented as an Oral Contribution at ACC.10, the 59th Annual Scientific Session of the American College of Cardiology. J Am Coll Cardiol 2010;55:A16.E147.
development for the treatment of ADHF, 8, 9 acts specifically on oxidized/haem-free sGC independently of nitric oxide by binding to the enzyme's haem pocket and mimicking the nitric-oxidebound haem group. 10 In animal studies, cinaciguat exerted potent vasodilation while preserving the glomerular filtration rate (GFR), 11 and had antihypertrophic and antifibrotic effects. 12 The first clinical study of cinaciguat in patients with ADHF demonstrated strong reductions in preload and afterload, with an increase in cardiac output and preservation of renal function. 13 The lack of a deleterious effect on renal and cardiac function despite a lowering of blood pressure in the clinical study suggests that cinaciguat may have unique properties. However, as the clinical study was not placebo controlled, it was unclear how much of the observed clinical improvement could be attributed to cinaciguat and how much was due to other interventions. The aim of the current placebocontrolled, double-blind, phase IIb study was to evaluate the haemodynamic effects and safety of i.v. cinaciguat (added to standard therapy) in patients with ADHF.
Methods
The study enrolled patients at 32 centres in 13 countries over a 15-month period from December 2007 to March 2009. The study was carried out in accordance with the Declaration of Helsinki and adhered to the International Conference on Harmonisation Good Clinical Practice guidelines. The ethics committees of all the participating centres approved the study protocol. All patients provided informed consent.
Patients
Patients aged ≥18 years were eligible for inclusion if they had acutely decompensated chronic congestive heart failure, requiring hospitalization, with a pre-existing need for right heart catheterization, and a pulmonary capillary wedge pressure (PCWP) ≥18 mmHg. Patients had to have a clinical indication for right heart catheterization, but the decision to use right heart catheterization in each individual patient was at the discretion of the investigator. Patients had to have had a clinical diagnosis of chronic heart failure for ≥3 months before study entry, left ventricular ejection fraction ,40% in the 6 months before study entry, and a history of heart failure hospitalization or requirement for i.v. diuretic treatment in the 12 months before study entry. Patients needed to have worsening dyspnoea symptoms or clinical evidence of volume overload leading to hospitalization at the time of enrolment. Patients were excluded if they had undergone cardiac surgery within the previous month or had any of the following: acute de novo heart failure; heart failure associated with pulmonary or valvular disease as the primary cause of heart failure; heart failure associated with congenital heart disease; pulmonary embolism or myocardial infarction within the previous 30 days; hypertrophic cardiomyopathy; unstable angina; acute inflammatory heart disease; cardiogenic shock; heart rate (HR) ≥120 b.p.m., systemic arterial systolic blood pressure (SBP) ,100 mmHg or .180 mmHg; significant liver disease (e.g. acute clinical hepatitis, chronic active hepatitis, cirrhosis; aspartate aminotransferase levels more than three times the upper limit of the normal range), or severe chronic kidney disease or renal failure (estimated GFR ,30 mL/min/1.73 m 2 ). A full list of inclusion and exclusion criteria is available as Supplementary material online.
Study plan
This was a multinational, placebo-controlled, double-blind, phase IIb study. All patients underwent screening, including physical examination and laboratory tests. Demographic data, medical history, concomitant medication use, and adverse events were also recorded. The maximum permitted length of time between admission to the emergency ward and start of treatment was 48 h. Patients were randomized in a 2:1 ratio to receive cinaciguat or placebo. Patients had undergone right heart catheterization ≥2 h before receiving study drug, and the first study measurements were taken ≥1 h after catheter insertion. A follow-up visit was scheduled for 30235 days after study inclusion.
Patients were valid for safety analysis if they had received at least one dose of study medication. If they also had at least one valid efficacy measurement at baseline and post-baseline, they were included in a modified intent-to-treat analysis. Patients were included in a per protocol titration (PPT) analysis if they were valid for the modified intent-to-treat analysis, had a valid PCWP measurement at baseline and at 8 h (or, if withdrawn because of the lack of efficacy, a valid PCWP measurement at any time post-baseline up to 8 h), and showed no major protocol deviations.
Blood pressure, HR, and invasive supine haemodynamic parameters were measured at baseline and during the study drug infusion (up to 48 h or the end of the infusion). Blood pressure and HR were also measured up to 8 h after stopping the study drug infusion. For PCWP, two separate baseline readings were taken to ensure that the haemodynamics were reproducible. Quality checks based on printed read-outs of haemodynamic recordings were performed by blinded central control. Blood samples were taken at baseline, 24 and 48 h or the end of the infusion. Patients also rated their dyspnoea on a visual analogue scale (VAS) at baseline, 8 and 48 h, and they rated changes in dyspnoea on a 7-point Likert scale at 8 and 48 h.
Treatment
Placebo or cinaciguat at a concentration of 50 mg/mL was administered as a continuous i.v. infusion for a titration phase of 8 h and a maintenance phase of 16 -40 h (Figure 1 ). The starting dose (i.e. initial infusion rate) of cinaciguat was 100 mg/h, and was up-or down-titrated at 2, 4, and 6 h according to tolerability, SBP, and HR ( Figure 2 ).
Concomitant medication
Dobutamine at low doses (≤4 mg/kg/min), intravenously administered diuretics, angiotensin-converting enzyme inhibitors, and beta-blockers were allowed during the infusion period. Intravenous diuretics were to be started at an individualized dose depending on clinical conditions and titrated according to the clinical response.
14 Levosimendan, vasodilators, vasoconstrictive agents, nitrates, and positive inotropic agents (except dobutamine at doses ≤4 mg/kg/min) were not allowed during the study and were to be stopped ≥3 h before the start of the study drug infusion. Phosphodiesterase type 5 inhibitors were not allowed during the study or in the 48 h before the start of the infusion. Strong cytochrome P450 2C8 inhibitors were also not allowed during the study and were to be stopped ≥24 h before the start of the infusion.
Outcome measures
The primary efficacy endpoint was a change in the PCWP from baseline to 8 h or the last post-baseline observation carried forward (LOCF) in the PPT cinaciguat population vs. placebo. Secondary exploratory endpoints included changes from baseline in haemodynamic parameters measured by right heart catheterization and dyspnoea vs. placebo. B-type natriuretic peptide (BNP) levels were also monitored.
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Safety monitoring
The following safety variables were recorded: HR, SBP, systemic arterial diastolic blood pressure, treatment-emergent adverse events, and treatment-emergent serious adverse events; estimated GFR (using the Modification of Diet in Renal Disease formula); laboratory parameters (troponin I concentrations were measured in a central laboratory and did not form part of standard care); electrocardiogram (ECG) parameters; mortality; and re-hospitalization.
Statistical analysis
The primary efficacy analysis was performed on the PPT population. Missing data were imputed using the LOCF method. The change in the PCWP from baseline to 8 h/LOCF in the PPT population was evaluated using analysis of covariance. Analysis of covariance was also used to analyse all secondary exploratory outcome measures except the Likert dyspnoea scale, which was assessed using a stratified Wilcoxon test. Using a standard deviation of 6.5 mmHg, a power of 90%, and a two-sided significance level of 5% with a 2:1 randomization, 168 randomized patients were required for the PPT population to detect a clinically relevant, placebo-adjusted difference of 3.5 mmHg for cinaciguat. The sample size was calculated using nQuery, version 6.0, module MTTOU-1 (Statistical Solutions, Saugus, MA, USA). An invalidity rate of 20% was assumed, and thus 210 patients were planned to be randomized.
The study was prematurely terminated after 158 patients had been screened. The protocol pre-specified that the study or single dose steps should be terminated if drug-related adverse events occurred that were so serious that the risk-benefit ratio was no longer acceptable, or if the results showed evidence of unacceptable risks. Termination was suggested by the independent Data Monitoring Committee and agreed upon by the Steering Committee and sponsor on the basis of a pronounced pharmacodynamic effect of cinaciguat. This effect led to a high incidence of non-sustained hypotensive events at all the doses studied except 50 -100 mg/h, which showed that there was a maximum tolerated dose in the study but that the study design did not allow the identification of the minimum effective dose. Data from 139 patients were judged to be valid for the primary PPT analysis of the PCWP. Using the same assumptions as above, the power of the study to detect a difference of 3.5 mmHg for cinaciguat was 85%.
Results

Study population
Of the 158 patients screened, 150 were eligible for inclusion ( Figure 3 ). Two randomized patients received no study medication, resulting in 148 patients valid for the analysis. These patients formed the safety population. Two additional patients were excluded from the modified intent-to-treat population [no haemodynamic assessment of PCWP post-baseline (n ¼ 1); took part in another trial (n ¼ 1)]. A further seven patients were excluded from the PPT analysis, most commonly because critical invasive haemodynamic measurements were deemed to be non-evaluable by the Adjudication Committee (n ¼ 4); other reasons included protocol violations and missing critical invasive haemodynamic measurements. The PPT population thus consisted of 139 patients. A further 33 patients were excluded from the per protocol maintenance (PPM) phase analysis, with the most common reason for exclusion from the PPM population being lack of a valid PCWP measurement during the maintenance phase [n ¼ 18 (cinaciguat, n ¼ 14; placebo, n ¼ 4)].
Patient demographics
Baseline clinical and haemodynamic parameters are shown in Table 1 for the safety population. Data were similar for the cinaciguat and placebo groups, except for the proportion of men, which was greater in the cinaciguat group. Because of the small number of women receiving cinaciguat (9 patients; 9.3%), sex-based statistical analysis was not performed. In line with the critically ill nature of the patients in this population, a high prevalence of prior morbidity and cardiovascular medication use was recorded. 
Primary efficacy
In total, 91.1% (82/90) of patients in the cinaciguat group and 95.9% (47/49) in the placebo group continued to receive the study drug at the end of the 8-h titration phase. The numbers of patients per dose group and planned time point are shown in Figure 1 . The mean baseline PCWP was 25.7 + 5.0 and 25.0 + 5.3 mmHg in the cinaciguat and placebo groups, respectively. The administration of cinaciguat resulted in a significant reduction in the mean PCWP from baseline to 8 h/LOCF compared with placebo (cinaciguat: 27.7 mmHg; placebo: 23.7 mmHg; difference: 4.0 mmHg; P , 0.0001) (Figure 4) . Last post-baseline observation carried forward was used for seven patients in the cinaciguat group and three patients in the placebo group.
Secondary exploratory parameters
The administration of cinaciguat resulted in statistically significant reductions in the systemic arterial mean blood pressure, right atrial pressure, mean pulmonary arterial pressure, and systemic and pulmonary vascular resistance (SVR and PVR, respectively) and significant increases in the cardiac index, from baseline to 8 h/LOCF compared with placebo (Table 2; Figure 4 ). These changes from baseline were maintained at 48 h/LOCF. Haemodynamic Figure 2 Dose titration scheme. *Up-titration was only performed during the titration phase. Up-titration from 400 to 600 mg/h was only performed if the SBP was ≥110 mmHg. After down-titration, no up-titration was permitted. † Observed in two consecutive measurements. PCWP, pulmonary capillary wedge pressure; SBP, systemic arterial systolic blood pressure.
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parameters by dose at the start of the maintenance phase are available as Supplementary material online.
Mean dyspnoea VAS scores at baseline were ,50 in both patient groups (cinaciguat: 46.3 + 26.2; placebo: 40.2 + 26.8). Scores at 8 h decreased by 17.7 and 15.5 with cinaciguat and placebo, respectively (difference: 2.2; P ¼ 0.50). The VAS scores at 48 h and the Likert scale results at 8 and 48 h also showed no statistically significant differences.
Median (inter-quartile range) BNP levels at baseline were 776 (306, 1309) pg/mL and 673 (317, 1210) pg/mL in the cinaciguat and placebo groups, respectively. Compared with baseline, the median change in the BNP level at 24 h was -160 (-415, +32) pg/mL in the cinaciguat group and -20 ( -99, +204) pg/mL in the placebo group; at 48 h, it was -127 (-465, +40) pg/mL in the cinaciguat group and -87 (-322, +9) pg/mL in the placebo group.
Safety
Hypotension (predefined as SBP ,90 mmHg, a reduction from baseline of ≥40 mmHg, or an adverse event related to hypotension) was observed in 71 patients (73.2%) receiving cinaciguat and in 13 patients (25.5%) receiving placebo. Hypotension occurred in 19 of the 26 patients who received a maximum dose of 600 mg/h cinaciguat, in 26 of the 32 patients who received a maximum dose of 400 mg/h, in the one patient who received a maximum dose of 300 mg/h, in 22 of the 28 patients who received a maximum dose of 200 mg/h, and in three of the ten patients who received a maximum dose of 100 mg/h. The heart rate increased by +5.4 + 11.6 b.p.m. with cinaciguat and +0.5 + 11.5 b.p.m. with placebo at 8 h, from baselines of 82 + 14 b.p.m. and 75 + 14 b.p.m., respectively. The SBP decreased to a greater extent in the cinaciguat group (-21.6 + 17.0 mmHg) than the placebo group ( -5.0 + 14.5 mmHg; Figure 4) . In an analysis of SBP changes from baseline by dose at the start of the maintenance phase (see Supplementary material online), no clear trend with dose was observed at 8 h, but at 24 h the highest dose (600 mg/ h) was associated with the greatest mean decrease in the SBP (231.7 mmHg). The study was stopped prematurely due to the high incidence of hypotension in the cinaciguat group. The dose at which hypotension frequently exceeded acceptable levels was ≥200 mg/h cinaciguat.
The mean treatment duration was 29.2 + 15.6 h with cinaciguat and 37.1 + 13.6 h with placebo. The incidence of treatmentemergent adverse events is shown in Table 3 . In most cases, hypotensive adverse events were classified as non-serious. One patient in the cinaciguat group had a hypotensive event during the 400 mg/h Cinaciguat, a soluble guanylate cyclase activator dose step that was deemed by the investigator to be serious and drug related; the event resolved after discontinuation of the study drug and infusion of saline. The mean duration of hypotensive events was 14.3 + 29.2 h in the cinaciguat group and 10.5 + 7.5 h in the placebo group. The mean time to the start of hypotensive adverse events was 6.3 + 6.4 h in the cinaciguat group and 14.5 + 14.5 h in the placebo group. In total, 49 patients in the cinaciguat group had 65 treatment-emergent hypotensive adverse events. Of these, 1, 8, 18, 2, 21, and 12 events started at cinaciguat doses of 50, 100, 200, 300, 400, and 600 mg/h, respectively. The remaining three events started within 1 day after stopping the cinaciguat infusion. Details of serious adverse events and hypotensive adverse events occurring at different cinaciguat dose steps are available as Supplementary material online.
Ventricular tachycardia occurred in six patients, all in the cinaciguat arm (two at a dose of 200 mg/h, one at a dose of 300 mg/h, one at a dose of 400 mg/h, and two after the infusion had been stopped). Five of the six events were mild or moderate in nature. In one of the patients, the ventricular tachycardia required treatment by cardioversion (documented as a serious adverse event). In the other five patients, non-sustained ventricular tachycardia was observed on the monitor but was not documented . ............ ............ ............ ............ ........... ............ ............ ............ ........... ............ ............ ............ ........... ............ .... Baseline data available for 89 and 50 patients in the cinaciguat and placebo groups, respectively. c In many of the countries included in the study, 'vasoprotective agents other than standard therapy' and 'other antihypertensives' included a range of treatments that are not clinically approved or widely scientifically acknowledged, for example homeopathic treatments.
by ECG. The events were not related to a specific dose level, duration of drug treatment, acute drops in blood pressure, or significant increases in the HR. For all patients in whom the events occurred, disturbances in the ventricular conduction were documented in baseline ECGs.
At baseline, the estimated GFR was similar in the cinaciguat and Treatment-emergent laboratory abnormalities are shown in Table 4 . Seventeen patients (11.5%) had troponin I levels ≥1 ng/ mL [cinaciguat, n ¼ 13 (13.4%); placebo, n ¼ 4 (7.8%)]. In 11 patients (7.4%), troponin I levels were already elevated before the administration of the study drug [cinaciguat, n ¼ 7 (7.2%); placebo, n ¼ 4 (7.8%)]. Thus, six patients in the cinaciguat group who had normal troponin I levels at baseline developed an increase in troponin I after starting the study drug infusion. The maximum doses of cinaciguat received by these patients before the troponin I elevations were 200, 400, and 600 mg/h in two cases each. Six patients in total had concomitant increases in creatine kinase or alanine aminotransferase levels [cinaciguat group, n ¼ 5 (5.2%); placebo group, n ¼ 1 (2.0%)]. In two patients (1.4%; one in each treatment group), serial ECG analyses showed evidence of myocardial ischaemia at the time of troponin I elevations. However, none of the patients with increased troponin I levels showed clinical signs or symptoms of myocardial ischaemia.
Ten patients (10.3%) in the cinaciguat group and two patients (3.9%) in the placebo group were re-hospitalized within 30235 days of randomization. The most common reason for re-hospitalization was cardiac failure (cinaciguat, n ¼ 7; placebo, n ¼ 1). The maximum doses received by the 10 patients in the cinaciguat group were 200 mg/h in five cases, 400 mg/h in two cases, and 600 mg/h in three cases. Two patients (2.1%) in the cinaciguat group and three patients (5.9%) in the placebo group died during the initial hospitalization within 30235 days of randomization; no deaths were considered to be related to the study medication.
Discussion
This multinational, phase IIb study of cinaciguat in patients with ADHF is the first placebo-controlled study with an sGC activator in humans. The study drug doses were selected based on phase I and proof-of-concept studies, 13, 15 and the titration scheme was chosen with the aim to help control blood pressure and maximize safety. The study met its primary efficacy endpoint, and secondary exploratory haemodynamic measures reflected rapid and sustained reduction in the PCWP. Large decreases in the right atrial pressure suggested that cinaciguat caused venous as well as arterial vasodilation. However, a pronounced pharmacodynamic effect of cinaciguat, which led to a high incidence of treatment-emergent LOCF, last post-baseline observation carried forward; MBP, systemic arterial mean blood pressure; PAP diast , pulmonary arterial diastolic pressure; PAP mean, mean pulmonary arterial pressure; PAP syst , pulmonary arterial systolic pressure; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance; RAP, right atrial pressure; SD, standard deviation; SVR, systemic vascular resistance. *The cinaciguat-placebo difference is statistically significant at P , 0.05.
hypotensive events at all the doses studied except 50-100 mg/h, was a major concern. It is possible that the concomitant use of diuretics and other blood pressure decreasing agents had an added, synergistic effect on preload, and it is noteworthy that the hypotensive episodes occurred despite permitted changes in concomitant therapy. Hypotension is a common adverse event in clinical studies of treatments for ADHF, but the incidence of hypotension in the current study was substantially greater than that observed in previously published studies. In clinical trials of i.v. nesiritide, hypotension was the most common adverse event recorded; in a study of patients receiving nesiritide for up to 7 days, 11-17% developed symptomatic hypotension and 12 -24% developed asymptomatic hypotension. 16, 17 Similarly, in the levosimendan Survival of Patients with Acute Heart Failure in Need of Intravenous Inotropic Support (SURVIVE) trial, hypotension, together with cardiac failure, was the most common treatment-emergent adverse event recorded in levosimendan-treated patients (15.5%). 18 Also, in a randomized, controlled trial of milrinone, sustained hypotension requiring intervention was the most common adverse event during the index hospitalization (10.7%). 19 In the Value of Endothelin Receptor Inhibition with Tezosentan in Acute Heart Failure Study (VERITAS) trials, hypotension occurred in 22.7% of tezosentan-treated patients up to 5 days after initiating treatment, and was the most common adverse event associated with discontinuation. 20 The hypotensive events suggest that these agents are more potent vasodilators than older, established agents; their use (particularly in dose-finding studies and at high-dose levels) therefore requires keen observation and a readiness to commence i.v. fluid administration when necessary. No significant differences in dyspnoea were observed between the cinaciguat and placebo groups in the current study. It is possible that this was due to patients being supine and receiving standard therapy including oxygen during the run-in period, and thus not being severely dyspnoeic even at baseline. As changes in diuretic doses in the first 8 h were not recorded, it cannot be ruled out that the similar improvements in dyspnoea might also have been partly due to different doses of diuretics.
Ventricular tachycardia was more common in the cinaciguat group than the placebo group (though five of the six cases were not confirmed by ECG). There was no difference in mortality between the cinaciguat and placebo groups at 30-35 days postrandomization. This is in contrast to inotropic agents, which have been associated with increased in-hospital mortality. 21 Adverse events deemed by the investigator to be related to the study drug. Cinaciguat, a soluble guanylate cyclase activator the number of deaths in the current study was low overall, meaning that any between-group differences may have been indiscernible. Re-hospitalization rates during the follow-up period of 30 -35 days were numerically higher in the cinaciguat group than the placebo group. Elevated troponin I was identified as a predictor of in-hospital mortality in two large patient populations enrolled in the ADHF National Registry (ADHERE) 22 and the Enhanced Feedback for Effective Cardiac Treatment (EFFECT) study. 23 In the current study, more patients had troponin I elevations in the cinaciguat group than in the placebo group. None of those patients showed clinical signs or symptoms of myocardial ischaemia, but the high incidence of episodes of hypotension and troponin I elevations may have favoured an increased rate of re-hospitalizations in the patients assigned to cinaciguat. Troponin I increases have been observed previously in patients with heart failure without myocardial infarction, and may reflect ongoing myocyte injury related to heart failure. 24 Limitations of this study include the fact that diuretic treatments during the study period were not recorded and that laboratory test data were not available for all patients. In addition, the proportion of patients who were on other vasodilators that were stopped before the study drug infusion was not recorded. Another potential limitation is the challenging patient population; compared with patients hospitalized with heart failure in ADHERE, 25 a higher proportion of patients in the current study had a left ventricular ejection fraction ,40% or moderate/severe impairment (100 vs. 54% in ADHERE). The use of right heart catheterization implies a difference between the studied patients and those hospitalized for acute heart failure in the real world as, generally, the patients who can be studied by right heart catheterization are more clinically stable. However, these types of studies are nevertheless mandatory to establish the mechanisms of action of the study drug, its effective doses, and its safety.
To be effective in ADHF, an ideal therapy should maintain the SBP and decrease the PVR. The results from the present study are consistent with cinaciguat activating sGC independently of nitric oxide, and cinaciguat administration led to a remarkable decrease in the PVR, but with an undesirable decrease in SBP. The next goal would be to identify the dose at which cinaciguat still decreases vascular resistance, but without altering the SBP.
In conclusion, the results of the current study indicate that cinaciguat is an effective pulmonary and systemic vasodilator in patients with ADHF, but the increase in hypotension associated with cinaciguat doses ≥200 mg/h is a major concern. For this reason, several phase II dose-finding studies in patients with ADHF were initiated to investigate the safety and efficacy of i.v. cinaciguat at fixed doses ,200 mg/h. However, those studies were also terminated recently because of excessive hypotension and recruitment difficulties. 26 Overall, the clinical results indicate that cinaciguat cannot be developed as an acute haemodynamic agent, but preclinical data suggest that sGC activators may also have long-term, pressure-independent organ-protective effects; 12,27 these pressure-independent effects should become the focus of future research.
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